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The toxicity of the protein synthesis inhibitor puromycin towards a number of human and Chinese hamster cell lines 
has been examined. In comparison to cells of human origin, Chinese hamster cells exhibited about 25-fold higher resis- 
tance towards puromycin. These differences appeared to be species related as all the cell lines from any one species showed 
similar sensitivity towards puromycin. The incorporation of PH]leucine in the hamster cell lines was accordingly found 
to be more resistant to the inhibitory effects of puromycin as compared to human cells. Studies on the cellular uptake 
of PH]puromycin showed that in comparison to human cells, the drug uptake/binding in the hamster cell lines was greatly 
reduced. However, protein synthesis in the extracts of hamster and human cells showed no significant differences in sensi- 
tivity towards puromycin. These results show that the observed species related differences in cellular toxicity to puromycin 
are due to differences in the cellular uptake/binding of the drug. 
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1. INTRODUCTION 
Over the last few years, we have been in- 
vestigating the mechanism of action of a variety of 
anticancer drugs in cultured mammalian cells 
[l-5]. During the course of these studies, it was 
observed that a number of anticarcinostatic drugs 
like mithramycin, chromomycin A3, colchicine, 
vinblastine, maytansine and rhodamine 123 ex- 
hibited large differences in their toxicity towards 
cultured cells from various species [3,5,6]. In 
general, cells of human origin were much more 
sensitive to these drugs in comparison to those of 
hamster/mouse origin [3,5,6]. Here, we report that 
such differences also exist for the protein synthesis 
inhibitor puromycin which causes premature chain 
termination by competing with aminoacyl-tRNA 
for binding to the nascent peptide chain [7,8]. Our 
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studies show that the observed differences in tox- 
icity of puromycin are caused by differences in the 
cellular uptake/binding of the drug between cells 
of the sensitive and resistant species. 
2. MATERIALS AND METHODS 
2.1. Cell lines and culture conditions 
The cell lines used in this study and their species of origin are 
as follows: CHO WT (wild-type) V79 and M3-1 are Chinese 
hamster cell lines established from ovary, lung and bone mar- 
row tissues, respectively [5,6]. HeLa (clone Ss) is a human 
epithelial cell line established from cervical carcinoma [5,6]. 
HT.1080 is a pseudodiploid human cell line obtained from the 
American Type Culture Collection (ATCC CCL 121). 
Rockville, MD [5,6]. M-6 is a human cell line established from 
malignant melanoma [5,6]. All of these cell lines were routinely 
grown as monolayer cultures in alpha minimum essential 
medium supplemented with 5% fetal bovine serum at 37°C in 
a 95% air-5% CO2 atmosphere by procedures described earlier 
[5&l. 
2.2. Determination of cellular toxicity towards puromycin 
Toxicity of different cell lines towards puromycin was deter- 
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mined by seeding CHO and HeLa cells into wells of 24-well 
tissue culture dishes containing different dilutions of the drug 
as described [5,6]. 
from Amersham (IL). All other chemicals used were of the 
highest purity available. 
2.3. Effect of puromycin on [-‘H]leucine incorporation 3. RESULTS AND DISCUSSION 
About 1 x IO6 cells from each cell type suspended in 1 ml 
medium were incubated with different concentrations of 
puromycin for 15 min at 37°C. 5 &i [3H]leucine (spec. act. 
50 Ci/mmol) was then added and the tubes were further in- 
cubated at 37°C for 30 min. At the end of the incubation 
period, 1 ml of 10% trichloroacetic acid was added to each 
tube, and the tubes were chilled in ice for 30 min. The 
precipitate so formed was filtered on GF/C filter papers (What- 
man) and washed 3 times with 5% ice-cold trichloroacetic acid. 
The filters were dried and counted after adding 3-4 ml of 
aqueous counting scintillation fluid (ACS) (Amersham). 
2.4. Cellular uptake of fH]puromycin 
For these studies, 1 day prior to the experiments, 5 x lo5 cells 
from each cell line were seeded (in duplicate for each time 
period and drug concentration) into wells of 24-well tissue 
culture dishes and incubated overnight at 37°C. Next day, the 
growth medium was carefully aspirated and 0.25 ml of a solu- 
tion of [3H]puromycin (spec. act. 11 Ci/mmol; final concentra- 
tion 3 or 7.5 &i/ml) in growth medium was added to each well. 
After the indicated period of incubation at 37”C, the radioac- 
tive medium was aspirated and the cells were washed three times 
with cold phosphate-buffered saline (containing per 1: 8 g NaCl, 
0.2 g KCl, 1.15 g NazHP04 and 0.085 g KHzPOd). The cells 
from each well were dissolved in 0.25 ml of a lysis mixture con- 
sisting of 0.5% deoxycholic acid in 0.1 N NaOH and the 
amount of radioactivity was measured after the addition of 
3-4 ml aqueous counting scintillant (Amersham Searle). Non- 
specific binding was measured by incubating [‘Hlpuromycin in 
24-well tissue culture dishes having no cells. This value was sub- 
tracted from the total binding to yield the actual binding/up- 
take of labelled drug. At the same time, the total number of 
cells in two wells of each cell line was determined by trypsiniza- 
tion and counting of aliquots in a Coulter counter. The uptake 
of [3H]puromycin in different cell lines was normalized for a 
constant cell number. 
2.5. Cell-free protein synthesis 
Fig.la shows the dose-response curves of a 
number of different cell lines, viz. HeLa, 
HT-1080, M-6 (human), CHO WT, V79 and M3-1 
(Chinese hamster) towards puromycin. In these ex- 
periments, relative plating efficiencies of the above 
cell lines were determined in growth medium con- 
taining different concentrations of the drug. As 
can be seen, the relative plating efficiencies of all 
three human cell lines ,decreased sharply between 
0.05 and 0.10 pg/ml of puromycin and at 
0.15 pg/ml, the survival was reduced to about 10% 
of the control (DUO) value. In contrast, the cell lines 
of Chinese hamster origin, viz. WT CHO, V79 and 
M3-1, were highly resistant (approx. 25fold) to 
puromycin (Dre approx. 4 yg/ml). Since all the cell 
lines from any one species showed similar sensitivi- 
ty to puromycin, it strongly indicated that the 
observed differences are characteristics of the 
species from which these cells are derived. The 
observed species-related differences in cellular tox- 
icity are specific for puromycin as similar dif- 
ferences were not seen for other protein synthesis 
inhibitors such as emetine (Gupta, R.S., un- 
published). To investigate the basis of such species- 
related differences in cellular toxicity, a number of 
studies were carried out. Since all the cell lines 
from any one species behaved similarly, further 
studies were carried out using only one represen- 
tative human (HeLa) and Chinese hamster (WT 
CHO) cell line. 
Protein synthesis in cell-free extracts was carried out as in 
[lO,l l] in a final volume of 0.05 ml which contained per ml: 
0.6 ml cell extracts, 0.9 pmol ATP, 0.18 pmol GTP, 0.19 pmol 
creatine phosphate, 1.2 mg creatine phosphokinase, 30 pmol 
Hepes, pH 7.5, IOpM dithiothreitol, 89,~mol KCI, 19 unla- 
belled amino acids 0.12 pmol each, 50 gCi of [3H]leucine (spec. 
act. 50 Ci/mmol) and the drug at the indicated concentrations. 
The reaction was started by addition of cell extracts. After 
40 min incubation at 34”C, the reactions were terminated by the 
addition of 0.5 ml of 10% trichloroacetic acid containing 3% 
casamino acids. The mixtures were heated in a water bath at 
95°C for 10 min and then chilled in ice. The precipitates were 
collected on glass fibre filters, washed with 5% trichloroacetic 
acid, dried and counted. 
2.6. Drugs and chemicals 
Puromycin hydrochloride was purchased from Sigma (St. 
Louis, MO). [‘H]Puromycin and [‘Hlleucine were purchased 
Since puromycin is a specific inhibitor of 
eukaryotic protein synthesis, the effect of different 
concentrations of puromycin on the incorporation 
of [3H]leucine in HeLa and WT CHO cells was 
determined. Results of these studies depicted in 
fig. 1 b show that in HeLa cells, puromycin inhibits 
the incorporation of [3H]leucine in a dose- 
dependent manner. Around 5 pg/ml puromycin, 
[3H]leucine incorporation is reduced to about 60% 
of control and at 25 pg/ml, to about 10% of con- 
trol. However, WT CHO cells were highly resistant 
to puromycin as no inhibition of [3H]leucine incor- 
poration was observed at 10 pg/ml drug, and even 
at 25 ,ug/ml, only slight (<20%) inhibition of in- 
corporation was seen. Thus, the effect of 
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Fig.1. (a) Dose-response curves showing the effect of increasing 
concentrations of puromycin on the relative plating efficiencies 
of HeLa (w), HT 1080 (w), M6 (M), WT CHO 
(-), V79 (a) and M3-1 (H). (b) Effect of 
different concentrations of puromycin on [3H]leucine 
incorporation in HeLa (H) and WT CHO (- ) cells. 
puromycin on [3H]1eucine incorporation paralleled 
its toxic effect on human and Chinese hamster cell 
lines. 
To understand the biochemical basis of the 
observed differences in sensitivity towards 
puromycin, we investigated the cellular uptake and 
binding of [3H]puromycin to HeLa and WT CHO 
cells. The results of these experiments are shown in 
fig.2. As can be seen, there was considerable 
binding of [3H]puromycin to HeLa cells which oc- 
curred in both a dose- and time-dependent man- 
ner. The binding at both puromycin 
concentrations [3 &i/ml (0.27 ,uM) and 
7.5 &i/ml (0.68 PM)] increased linearly with 
time. However, in WT CHO cells, no significant 
binding of [3H]puromycin at these concentrations 
of the drug was detected. The results of these 
studies therefore indicate that the species-related 
differences in the cellular toxicity of puromycin 
could be due to differences in the drug uptake/bin- 
ding between the two cell types. 
To determine whether any of the observed dif- 
ferences in cellular toxicity were caused by dif- 
TIME (min 1 
Fig.2. Binding of [‘Hlpuromycin to HeLa (O-0, ti) and 
WT CHO (-. CI) cells. [‘H]Puromycin diluted in 
growth medium (3 &i/ml, circles; and 7.5 &i/ml, triangles) 
was added to cells and the uptake was measured as described 
[9]. HeLa (open symbols), WT CHO (closed symbols). 
ferences in the sensitivity of the protein synthesis 
machinery to this drug, the effect of different con- 
centrations of puromycin on in vitro protein syn- 
thesis in extracts of human and hamster cells was 
examined. Results of these studies presented in 
table 1 indicate that puromycin inhibited incor- 
poration of [3H]leucine into proteins in vitro in 
both WT CHO and HeLa cell extracts to the same 
extent. These results provide strong evidence that 
the observed differences between human and 
Chinese hamster cells in cellular toxicity of 
puromycin are not caused by differences in the 
protein synthetic machinery of the two cell types. 
In view of these results, the species differences in 
cellular toxicity to puromycin are most likely caus- 
ed by differences in the drug’s cellular up- 
take/binding. 
In addition to puromycin, cultured cells of 
Chinese hamster and human origin show large dif- 
ferences in cellular toxicity for a number of other 
drugs, including colchicine, chromomycin A3, 
maytansine, mithramycin, vinblastine, tax01 and 
rhodamine 123 [5,6,9]. For most of the drugs for 
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Table 1 
Effects of puromycin on in vitro protein synthesis 
[Puromycin] Human (HeLa) cells Chinese hamster cells 
&g/ml) (CHG) 
[3H]Leucine % 
incorporated inhibition [3H]Leucine % 
(cpm) incorporated inhibition 
(cpm) 
0 (control) 8300 0 14300 0 
50 5500 33.8 8300 42 
100 3320 60.0 5800 59.5 
200 2500 69.9 4400 69.3 
500 1700 79.6 3500 15.6 
Protein synthesis in cell-free extracts was carried out as described in 
section 2. The result shown above is an average of three replicates 
which differed from each other by less than 10% 
which species-related differences in cellular toxici- 
ty are observed, the mutants exhibiting a 
multidrug-resistant phenotype have also been 
reported to show increased resistance [4,12- 151. 
Recent studies from our laboratory indicate that 
the species-related differences in toxicity for the 
above drugs are apparently caused by a similar 
mechanism to that responsible for the MDR 
phenotype [16]. This view is supported by the 
observation that the resistance of hamster cells to 
the above drugs as well as the reduced drug up- 
take/binding could be restored to the sensitive 
human cell’s level in the presence of non-toxic 
doses of verapamil [ 161, a calcium channel block- 
ing agent which is known to cause reversal of the 
multidrug-resistance phenotype [ 17,181. 
For many of the drugs for which differences in 
cellular toxicity are observed between human and 
Chinese hamster cells viz. mithramycin, 
chromomycin A3, olivomycin [6] and cardiac 
glycosides [9], corresponding differences at the 
species level have also been observed [9,19,20]. 
Therefore, it is likely that the sensitivity/toxicity of 
humans to puromycin may be much greater in 
comparison to rodent species which are commonly 
employed to evaluate drug toxicity. 
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